A conundrum of honeycombing: challenges in tumor size estimation in patients with honeycombing in the lung

Sana Vahidy,Raoul Pereira,Sebastiao Nunes Martins-Filho,Meena Kalluri

DOI: https://doi.org/10.21037/jtd-24-437

2024-06-02

Journal of Thoracic Disease

Abstract:Sana Vahidy 1 , Raoul Pereira 2 , Sebastiao Nunes Martins-Filho 3 , Meena Kalluri 1 1 Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; 2 Department of Radiology and Diagnostic Imaging, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; 3 Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada Comment on: Ishizawa H, Matsuda Y, Ohno Y, et al . Honeycomb lung is a major risk factor for preoperative radiological tumor size underestimation in patients with primary lung cancer. J Thorac Dis 2023;15:516-28. Keywords: Honeycombing; interstitial lung disease (ILD); interstitial lung diseases (ILDs) Submitted Mar 16, 2024. Accepted for publication Mar 28, 2024. Published online May 27, 2024. doi: 10.21037/jtd-24-437 Interstitial lung diseases (ILDs) are a heterogeneous group of lung disorders characterized by inflammation and/or fibrosis. ILD represents a diverse group of over 200 lung diseases of varying etiologies (1-3). Idiopathic pulmonary fibrosis (IPF) is the most common ILD characterized by a usual interstitial pneumonia (UIP) pattern on imaging and histology (1). Patients with IPF are typically male with an active or former smoking history. IPF is one form of idiopathic interstitial pneumonia (IIP) (3). Other forms of IIP include nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), and lymphocytic interstitial pneumonia (LIP), among others (3). ILDs can also be secondary to connective tissue disease, occupational, drug-induced, and antigen-associated hypersensitivity pneumonitis (1). Lung cancer is a common comorbidity in ILD (4-6). A recent systematic review and meta-analysis found an increased risk of lung cancer in patients with IPF even after adjustment for age, smoking, and sex (4). In patients with IPF, reported lung cancer prevalence ranges from 3% to 48% (4-7). It is difficult to determine the true incidence and prevalence of lung cancer in patients with ILD due to confounding factors in many of the reported studies. The cancer typically presents as peripheral lesions, mostly in the inferior pulmonary lobes, either close to or within the ILD areas (5-7). Hence, it is quite likely that the presence of fibrosis on chest imaging can influence tumor size estimation, which is pivotal to clinical decision-making, thus significantly impacting cancer care and prognosis in ILD. One study published in 2016 demonstrated a greater frequency of preoperative tumor size underestimation of 10 mm in IIPs than without IIPs (8). The authors attributed this underestimation to the tumor spread in regions of honeycomb lung (8). The high prevalence of lung cancer in ILD is likely related to many shared risk factors among both conditions (4-7). Smoking is a well-recognized risk factor for both lung cancer and ILD, in particular for IPF. Other potential shared risks include genetics, environmental exposures, and immune system dysfunction (9). Mechanical forces in the fibrotic regions of the lung have also been proposed as a novel risk factor for cancer development in ILD (9). It is hypothesized that these mechanical forces arising from the fibrotic areas may impact cell regulation and proliferation leading to cancerogenesis (9). It is possible this is exacerbated in areas with more significant architectural distortion including regions with honeycombing. However, there is a lack of studies on lung cancer and tumor infiltration in regions of honeycombing. The gold standard therapeutic option for early-stage non-small cell lung cancer (NSCLC) is surgical resection with lymph node dissection. However, surgical resection is challenging in patients with underlying ILD due to a higher risk of morbidity and mortality compared to patients without ILD (5,6,10,11). Alternative treatments like stereotactic radiotherapy or radiofrequency ablation may be considered for ILD patients who are unfit for surgery, but these options also carry risks of acute exacerbation and pneumonitis (12-14). Similarly, many chemotherapy agents are associated with pulmonary toxicity, exacerbating underlying ILD or causing new-onset ILD in the form of drug-induced pneumonitis (12-14). Consequently, all therapeutic options pose increased risks of disease progression and mortality in ILD patients, whose prognosis is often poor even at the initiation of treatment (11). Given these considerations, accurate tumor size identification becomes paramount to effectively selecting therapies that balance benefits and risks. The study conducted by Ishizawa and his colleagues' sheds light on the challenges faced in accurately determining the size of tumors -Abstract Truncated-

respiratory system